Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISTH 2022 | The importance of liver health in patients participating in hemophilia gene therapy clinical trials

Brian O’Mahony • 11 Jul 2022
ISTH 2022
Hemophilia Non-Malignant

Brian O’Mahony, Irish Haemophilia Society, Dublin, Ireland, briefly discusses the importance of liver health in patients before, during and after participation in hemophilia gene therapy clinical trials. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.

More from Brian O’Mahony

Empowering patients with hemophilia to make choices about gene therapy 0:50
Empowering patients with hemophilia to make choices about gene therapy
Brian O’Mahony • 11 Jul 2022
The role of social media in patient advocacy in hemophilia 0:44
The role of social media in patient advocacy in hemophilia
Brian O’Mahony • 11 Jul 2022
International collaborations working to improve hemophilia care 1:00
International collaborations working to improve hemophilia care
Brian O’Mahony • 11 Jul 2022
Key steps to improve opportunities for gene therapy in patients with hemophilia 0:31
Key steps to improve opportunities for gene therapy in patients with hemophilia
Brian O’Mahony • 11 Jul 2022

Related Videos

Acute chest syndrome in sickle cell disease: pathophysiology, management, and prevention 4:49
Acute chest syndrome in sickle cell disease: pathophysiology, management, and prevention
Subarna Chakravorty • 3 Nov 2025
The role of inflammation in SCD pathophysiology and potential avenues for targeting it 6:48
The role of inflammation in SCD pathophysiology and potential avenues for targeting it
Subarna Chakravorty • 3 Nov 2025
The management of thalassemia in India 2:16
The management of thalassemia in India
Shruti Kakkar • 15 Oct 2025
The potential role of thalidomide in the treatment of thalassemia 2:33
The potential role of thalidomide in the treatment of thalassemia
Shruti Kakkar • 15 Oct 2025
The content of VJHemOnc is intended for healthcare professionals